2024-12-02 14:40:10 ET
DENVER, Colo., Dec 02, 2024 ( 247marketnews.com )- MoBot’s recent alerts included; Senti Biosciences (NASDAQ: SNTI ), Ocean Power (NYSE: OPTT ), KULR (NYSE: KULR ), ParaZero Technologies (NASDAQ: PRZO ), Fossil Group (NASDAQ: FOSL ), and Esperion Therapeutics (NASDAQ: ESPR ) were among the MoBot alert listings that reached new 52-week highs in today’s trading.
Senti Biosciences (NASDAQ: SNTI ) reported entering into a securities purchase agreement to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock through a private investment in public equity (the “PIPE”) financing, which is expected to raise approximately $37.6 million, less offering expenses, for Senti Bio.
Senti Biosciences (NASDAQ: SNTI) triggered Mobot at $2.583, this morning, and Senti set a new 52-week high of $16.94.
MoBot alerted Ocean Power (NYSE: OPTT ) Nov 22 at $0.174 and today it hit $0.53. Ocean Power hit 52-week high of $0.816, today, and is scheduled to publish its financial results report after today’s market close.
KULR (NYSE: KULR ) was also alerted on Nov 22, at $0.459 and today it hit $1.96 in the premarket session and set its official 52-week high of $1.7499, during the regular trading session.
ParaZero Technologies (NASDAQ: PRZO ) announced, this morning, that it received Design Verification Report (DVR) approval from the European Union Aviation Safety Agency (EASA) for its SafeAir M-300 Pro and SafeAir M-350 Pro parachute safety kits.
ParaZero (NASDAQ: PRZO) was alerted by MoBot on Nov 26, at $0.714, and today it hit a new 52-week high of $2.2699.
Fossil Group (NASDAQ: FOSL ) was alerted on Nov 25, at $1.304, and it set 52-week high of $2.61.
MoBot alerted Esperion Therapeutics (NASDAQ: ESPR ) move on Oct 02, at $1.775, and it set a new 52-week high of $3.44, today, after announcing that it filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk.
Sheldon Koenig, President and CEO of Experion, stated, “These submissions mark another pivotal milestone towards bringing our potentially lifesaving medications to the millions of patients around the world who need it.
“Heart disease remains the number one cause of death globally, so we look forward to the opportunity to provide NEXLETOL and NEXLIZET as LDL cholesterol lowering and cardiovascular risk reduction treatment options for healthcare providers and patients in Canada.”
Please go to www.247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.
The post December is Already Lit appeared first on 24/7 MarketNews .
For further details see:
December is Already Lit
